Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients.

Like Comment

Genome complexity has been associated with poor outcome in patients with chronic lymphocytic leukemia (CLL). Previous cooperative studies established five abnormalities as the cut-off that best predicts an adverse evolution by chromosome banding analysis (CBA) and genomic microarrays (GM). However, data comparing risk stratification by both methods are scarce. Herein, we assessed a cohort of 340 untreated CLL patients highly enriched in cases with complex karyotype (CK, 46.5%) with parallel CBA and GM studies. Abnormalities found by both techniques were compared. Prognostic stratification in three risk groups based on genomic complexity [0-2, 3-4 and ≥5 abnormalities] was also analyzed. No significant differences in the percentage of patients classified into each category were detected, but only a moderate agreement was observed between methods when focusing in individual cases (κ=0.507; p.

View the full article @ Haematologica

Get PDF with LibKey

Authors: Silvia Ramos-Campoy, Anna Puiggros, Sílvia Beà, Sandrine Bougeon, María José Larráyoz, Dolors Costa, Helen Parker, Gian Matteo Rigolin, Margarita Ortega, María Laura Blanco, Rosa Collado, Rocío Salgado, Tycho Baumann, Eva Gimeno, Carolina Moreno, Francesc Bosch, Xavier Calvo, María José Calasanz, Antonio Cuneo, Jonathan C Strefford, Florence Nguyen-Khac, David Oscier, Claudia Haferlach, Jacqueline Schoumans, Blanca Espinet


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6577 Contributions
0 Following